Latest Oncology News

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021

Jamie Cesanek

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Colleen Moretti

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

September 19th 2021

Ryan McDonald

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

September 19th 2021

Nichole Tucker

Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.

Ribociclib/Letrozole Combo Yields Significant OS Benefit in Postmenopausal HR+/HER2- Advanced Breast Cancer

Ribociclib/Letrozole Combo Yields Significant OS Benefit in Postmenopausal HR+/HER2- Advanced Breast Cancer

September 19th 2021

Courtney Marabella

The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.

Latest Oncology Videos

All Oncology News

A Changing Tide for Patients With Myelofibrosis

September 14th 2021

Brittany Lovely

The hallmarks of myelofibrosis—including clonal myeloproliferation, bone marrow fibrosis, anemia, splenomegaly, and constitutional symptoms—are associated with risk of morbidity and mortality; however, the recent advent of novel combinations and sequencing strategies have built on the foundation of care established with JAK2 inhibitors.

Dosing Strategies Help Personalize Care in HER2+ Breast Cancer

September 14th 2021

Ryan Scott

Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.

Dismutase Mimetic/SBRT Continues to Impress in Locally Advanced Pancreatic Cancer

September 14th 2021

Kristi Rosa

The dismutase mimetic avasopasem manganese was found to improve overall survival, progression-free survival, local disease control, time to metastases, and tumor response rate compared with placebo in patients with unresectable or borderline resectable locally advanced pancreatic cancer who were undergoing stereotactic body radiation.

Transfusion Independence With Momelotinib Could Inform Treatment Decisions in Myelofibrosis

September 14th 2021

Jessica Hergert

The investigational JAK inhibitor momelotinib is effective at treating anemia in patients with myelofibrosis, resulting in improved rates of transfusion independence compared with ruxolitinib.

LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

September 14th 2021

Kyle Doherty

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

Updates and Advances in the Treatment of Metastatic HER2+ Breast Cancer

September 14th 2021

OncLive Staff

Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Management of Early-Stage HER2-Positive Breast Cancer

September 14th 2021

OncLive Staff

In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Challenges and Unmet Needs in the Treatment of HER2-Positive Breast Cancer

September 14th 2021

OncLive Staff

In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

Dr. Mogal on Patient Selection for Cytoreductive Surgery in CRC

September 13th 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the importance of patient selection for cytoreductive surgery in colorectal cancer with peritoneal involvement.

Dr. Sborov on the Toxicities Associated With Novel Therapies in Multiple Myeloma

September 13th 2021

Douglas W. Sborov, MD, MS

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

Dr. Patil on the Development of KRAS G12C Inhibitors in Lung Cancer

September 13th 2021

Pradnya D. Patil, MD, FACP

Pradnya D. Patil, MD, FACP, discusses the development of KRAS G12C inhibitors in lung cancer.

Dr. Choueiri on the Results of the KEYNOTE-564 Study in RCC

September 13th 2021

Toni Choueiri, MD, Dana-Farber Cancer Institute

Toni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.

Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

September 13th 2021

Karim Chamie, MD

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Dr. Shore on the Results of the ENACT Trial in Prostate Cancer

September 13th 2021

Neal Shore, MD, FACS

Neal D. Shore, MD, FACS, discusses the results of the randomized, open label, phase 2 ENACT trial in prostate cancer.

UGN-101 Induction Produces Durable Responses in Low-Grade Upper Tract Urothelial Carcinoma

September 13th 2021

Kristi Rosa

Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.

See All News